Prevalence, Management and Follow-up of Patients With Addiction to Opioid Analgesics

May 4, 2018 updated by: University Hospital, Montpellier

The demand for addiction care for patients with addiction to analgesics increases with the number of prescription of analgesics grade 2; this is a public health problem There is no support for repositories to date in the context of addiction analgesics grade 2.

Risk factors of misuse as well as diagnostic tools were identified.

Study Overview

Status

Completed

Conditions

Detailed Description

The demand for addiction care for patients with addiction to analgesics increases with the number of prescription of analgesics grade 2; this is a public health problem There is no support for repositories to date in the context of addiction analgesics grade 2.

Risk factors of misuse as well as diagnostic tools were identified. The objectives of our research are to determine the characteristics of the individuals suffering from an addiction to analgesics of level 2 followed in consultation of addictology in the hospital of Montpellier and Nimes and to describe the type of follow-up proposed to the patients in these two centers. It is a retrospective and descriptive study.

As part of this research, we will solicit all the patients followed in consultation of addictology or in hospitalization to the hospital of Montpellier or Nîmes for an addiction to the analgesics of grade 2 between the 1st of January 2014 and the 10th of July 2017 with requests of management for withdrawal or reduction of doses, opioid analgesics in the absence of pain or in chronic non-cancer pain, opioid analgesics to avoid withdrawal syndrome or hyperalgesia and consumptions chronic to dosages inadequate to the functional complaint evaluated by the rhumatology or algology services.

The data are collected in the medical file at the two participating institutions (Montpellier and Nîmes) and if necessary, patients not seen in consultation for more than 6 months will be recontacted.

Study Type

Observational

Enrollment (Actual)

64

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Montpellier, France, 34295
        • Uhmontpellier

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients attending addictology or hospitalization in Montpellier or Nîmes for an addiction to analgesics grade 2 between the 1st ofJanuary 2014 and the 22th of january 2017

Description

Inclusion Criteria:

  • Requests for management for weaning or reduction of doses
  • Take opioid analgesics in the absence of pain or as part of chronic non-cancer pain
  • Opioid analgesics to prevent withdrawal syndrome or hyperalgesia
  • Chronic consumption at inadequate dosages compared to the functional complaint evaluated by the MPR / Algologie services
  • Patients over 18 years and who agree with the study

Exclusion criteria:

  • language barrier
  • severe cognitive and / or psychiatric disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
50/5000 Prevalence of demand for care in addictology
Time Frame: 1 day
Prevalence of demand for addictive care in subjects with addiction to analgesics in level 2
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Types of support proposed
Time Frame: 1 day
Types of support proposed
1 day
Assessment of analgesic dependence
Time Frame: 1 day
Assessment of analgesic dependence
1 day
History of analgesic use
Time Frame: 1 day
History of analgesic use
1 day
quality of life
Time Frame: 1 day
quality of life
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Montpellier

Investigators

  • Principal Investigator: TARUFFI Floriane, Doctor, University Hospital, Montpellier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2014

Primary Completion (Actual)

July 31, 2017

Study Completion (Actual)

March 30, 2018

Study Registration Dates

First Submitted

September 26, 2017

First Submitted That Met QC Criteria

September 28, 2017

First Posted (Actual)

September 29, 2017

Study Record Updates

Last Update Posted (Actual)

May 7, 2018

Last Update Submitted That Met QC Criteria

May 4, 2018

Last Verified

September 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RECHMPL17_0305

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

NC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Analgesics Grade 2's Addiction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe